



Corporate Presentation
September 2018



Disclaimer

- This document is prepared by THERACLION(the “Company”) only for the purpose of this presentation. The information contained in this document is confidential and may not be reproduced or redistributed, directly or indirectly, to any person, or published, in whole or in part, for any reason, without the consent of the Company. Neither this document nor any copy of it may be taken, transmitted into or distributed in the United States of America, Canada, Japan or Australia, nor may it be distributed or redistributed to a resident of these countries. Non-compliance with these restrictions may result in the violation of legal restrictions of the United States of America or of other jurisdictions.
- The Company disclaims any obligation or undertaking to provide any update to this Presentation. The Company disclaims any obligation and liability for the information contained in this Presentation or for any use of this information. The information contained in this Presentation has not been subject to independent verification. No representation, warranty or undertaking, express or implied, is made to the readers of this Presentation by the Company. In particular, no representation, warranty or undertaking, express or implied, is given regarding the accuracy, completeness or reliability of the information, opinions and forward-looking information included in this Presentation.
- This document contains forward-looking statements and estimates made by the Company, including with respect to the anticipated future performance of the Company and the market in which it operates. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond the Company's control. Therefore, actual results, the financial condition, performance or achievements of THERACLION, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Forward-looking statements, forecasts and estimates only speak as of the date of this forward-looking statement, and no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. The Company disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the Company's expectations with regard thereto, or any events, or changes in conditions or circumstances on which any such statement, forecast or estimate is based.
- This document does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company, nor shall any part of it nor the fact of its distribution form part of or be relied on in connection with any contract or investment decision relating thereto, nor does it constitute a recommendation regarding the securities of the Company. THERACLION'S securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “Securities Act”) and may not be offered or sold in the United States absent registration under the Securities Act or an exemption from registration.
- This document is not intended to provide a complete analysis of the financial, business and prospective position of THERACLION. Other public information regarding THERACLION, including risk factors, are available on THERACLION's website (www.theraclion.com) and this document should be read in conjunction therewith.

Echopulse System



- Mobile Robotic System System
- Real time image controle, visualisation: <1mm accuracy
- Abulatory care in U/S room (no O/R)
- Surgeon-Ready Intuitive Touchscreen UIF
- Developped for Breast, Thyroids... And Veins
- Research on Cancer on Going (I/O,...)

U/S probe for imaging
HIFU Transducer for treatment



Theraclion

Company profile

Echopulse®: Non-invasive HIFU technology

- Alternative to 8 M invasive or minimal invasive surgeries WW each year
- **CE** marked in 2012; **45 sites as of September 2018 including 7 clinical units**
- Recurring revenues from disposables and service

Operations

- WW locations: Frankfurt, London, Milan, Hong Kong, based in Malakoff, France
- **JV China** with Furui Medical
- **25** employees, **>50%** dedicated to R&D and clinical trials
- Over **100** active patents within **20** patent families (on Echopulse® system and consumable)
- Listed on Paris Euronext Growth (ALTHE)

Echopulse® and EPack



Recent achievements

- '1H '18: routine clinical treatments 447 +89%
- '17: 13 New Echotherapy centers +62%
- 1H'18: €0,9M Revenues +61%
- German population covered @ 20M
- U.S. Breast pivotal study enrolling patients 6 sites, 80%
- **First BCa treatments on Metastatic Breast Cancer for combination Echotherapy and Immunotherapy (Pembrolizumab), ASCO-SITC**
- Varicose Veins Study completed, end point exceeded
- **VV Filing CE/FDA expected End 2018**

Addressing Large Global Markets

Replacing surgery & mini-invasive with non-invasive

Experience and footprint from BFA & Thyroid to quickly enter vein market

Breast Fibroadenoma



Thyroid nodules



Varicose veins



Game changer: Vein already existing \$500M Device Market & OOP payments helps rapid market penetration


1.4M surgeries/y
2.1B healthcare costs/y
<50 M Device Market

1.6M surgeries/y
4B healthcare costs/y
+/-100M Device Market

5M procedures/y
9B healthcare costs/y
>500M Device Market

Echotherapy 45 sites WW

Worldwide Presence as of September 2018



S Sales : 26 R Renting : 2 P Pay per use : 10 C Clinical : 7

Varicose Veins: Patient 4

Female, refluxing stump + neovascularization after surgery



Before treatment



Post-HIFU



at D3



at M3

Important aesthetic improvement at D3 and M3

Varicose Veins: Patient 47

95 yo Male , Open Ulcer + 10 years of Surgery, Sc, Bandage TT.



- Before HIFU: pain, smell, hard skin, Cold leg, suppurations

- After HIFU: no pain, no smell, soft skin, normal temperature, no suppurations

Treated in <1h patient cycle time un treatable patient



Thank you